COMMD1 protein expression and outcome.

<p>Representative examples of low (A) and high (B) expression levels of COMMD1 in FFPE DLBCL tissue (original magnifications 100×, and 400×). C–D. Outcome according to COMMD1 expression in the trial specific TMA cohort. PFS in in the whole TMA cohort (C) and in the GCB subgroup (D). E–F. Outcome according COMMD1 expression in the validation cohort. PFS in in the whole validation cohort (E) and in the GCB subgroup (F). The cutoff point (staining coverage of 8.9%) for survival outcomes (COMMD1 low vs high) was selected by the ROC curve analysis in the training set, and then applied also to validation cohort.</p

Survival of DLBCL patients according to genomic aberrations.

<p>PFS (A and C) and lymphoma-associated OS (B and D) rates according to indicated genomic aberration.</p

Expression of genes associated with amplifications in 2p15 and 18q12.2 locuses.

<p>Boxes contain expression values between the 25^th and 75^th percentile in the tumour subgroup. The extremes denoted by asterisks represent maximum and minimum expression values.</p

Genome-wide overview of recurrent gains and losses.

<p>Genome-wide overview of recurrent gains and losses.</p

Baseline characteristics according to COMMD1 expression in TMA and validation cohorts.

<p>Baseline characteristics according to COMMD1 expression in TMA and validation cohorts.</p

Patient characteristics in the screening cohort.

<p>Patient characteristics in the screening cohort.</p

PFS according to <i>COMMD1</i> expression.

<p>A. PFS according to exon array based <i>COMMD1</i> expression values. B. PFS according to quantitative PCR analysis based <i>COMMD1</i> expression values. In both A and B, the ideal cutoff values have been calculated using ROC curve analyses. In A the estimated area under the curve (AUC) was 0.717 (<i>p</i> = 0.063, 95% CI 0.531–0.903). In B the AUC was 0.759 (<i>p</i> = 0.062, 95% CI 0.468–1.000).</p